Reviews Cetuximab


No reviews yet.

Erbitux Drug Description
ERBITUX®
(cetuximab) Solution for Intravenous Infusion

WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST
Infusion Reactions: Serious infusion reactions occurred with the administration
of Erbitux in approximately 3% of patients in clinical trials, with fatal
outcome reported in less than 1 in 1000. [See WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS.] Immediately interrupt
and permanently discontinue Erbitux infusion for serious infusion reactions.
[See WARNINGS AND PRECAUTIONS and DOSAGE
AND ADMINISTRATION.]
Cardiopulmonary Arrest: Cardiopulmonary arrest and/or sudden death occurred
in 2% of 208 patients with squamous cell carcinoma of the head and neck treated
with radiation therapy and Erbitux. Closely monitor serum electrolytes, including
serum magnesium, potassium, and calcium, during and after Erbitux. [See WARNINGS
AND PRECAUTIONS.]

DRUG DESCRIPTION



What are the possible side effects of cetuximab (Erbitux)?

Some people receiving a cetuximab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel short of breath, weak or dizzy, nauseated, itchy, or have wheezing, noisy breathing, or a hoarse voice during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Erbitux »




Erbitux (cetuximab) is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.
Erbitux is a sterile, clear, colorless liquid of pH 7.0 to 7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates. Erbitux is supplied at a concentration of 2 mg/mL in either 100 mg (50 mL) or 200 mg (100 mL), single-use vials. Cetuximab is formulated in a preservative-free solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, 0.41 mg/mL sodium phosphate monobasic monohydrate, and Water for Injection, USP.
Last reviewed on RxList: 8/3/2009




Erbitux Drug Description
ERBITUX®
(cetuximab) Solution for Intravenous Infusion

WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST
Infusion Reactions: Serious infusion reactions occurred with the administration
of Erbitux in approximately 3% of patients in clinical trials, with fatal
outcome reported in less than 1 in 1000. [See WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS.] Immediately interrupt
and permanently discontinue Erbitux infusion for serious infusion reactions.
[See WARNINGS AND PRECAUTIONS and DOSAGE
AND ADMINISTRATION.]
Cardiopulmonary Arrest: Cardiopulmonary arrest and/or sudden death occurred
in 2% of 208 patients with squamous cell carcinoma of the head and neck treated
with radiation therapy and Erbitux. Closely monitor serum electrolytes, including
serum magnesium, potassium, and calcium, during and after Erbitux. [See WARNINGS
AND PRECAUTIONS.]

DRUG DESCRIPTION



What are the possible side effects of cetuximab (Erbitux)?

Some people receiving a cetuximab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel short of breath, weak or dizzy, nauseated, itchy, or have wheezing, noisy breathing, or a hoarse voice during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Erbitux »




Erbitux (cetuximab) is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.
Erbitux is a sterile, clear, colorless liquid of pH 7.0 to 7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates. Erbitux is supplied at a concentration of 2 mg/mL in either 100 mg (50 mL) or 200 mg (100 mL), single-use vials. Cetuximab is formulated in a preservative-free solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, 0.41 mg/mL sodium phosphate monobasic monohydrate, and Water for Injection, USP.
Last reviewed on RxList: 8/3/2009




Erbitux Drug Description
ERBITUX®
(cetuximab) Solution for Intravenous Infusion

WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST
Infusion Reactions: Serious infusion reactions occurred with the administration
of Erbitux in approximately 3% of patients in clinical trials, with fatal
outcome reported in less than 1 in 1000. [See WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS.] Immediately interrupt
and permanently discontinue Erbitux infusion for serious infusion reactions.
[See WARNINGS AND PRECAUTIONS and DOSAGE
AND ADMINISTRATION.]
Cardiopulmonary Arrest: Cardiopulmonary arrest and/or sudden death occurred
in 2% of 208 patients with squamous cell carcinoma of the head and neck treated
with radiation therapy and Erbitux. Closely monitor serum electrolytes, including
serum magnesium, potassium, and calcium, during and after Erbitux. [See WARNINGS
AND PRECAUTIONS.]

DRUG DESCRIPTION



What are the possible side effects of cetuximab (Erbitux)?

Some people receiving a cetuximab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel short of breath, weak or dizzy, nauseated, itchy, or have wheezing, noisy breathing, or a hoarse voice during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Erbitux »




Erbitux (cetuximab) is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.
Erbitux is a sterile, clear, colorless liquid of pH 7.0 to 7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates. Erbitux is supplied at a concentration of 2 mg/mL in either 100 mg (50 mL) or 200 mg (100 mL), single-use vials. Cetuximab is formulated in a preservative-free solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, 0.41 mg/mL sodium phosphate monobasic monohydrate, and Water for Injection, USP.
Last reviewed on RxList: 8/3/2009




Erbitux Drug Description
ERBITUX®
(cetuximab) Solution for Intravenous Infusion

WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST
Infusion Reactions: Serious infusion reactions occurred with the administration
of Erbitux in approximately 3% of patients in clinical trials, with fatal
outcome reported in less than 1 in 1000. [See WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS.] Immediately interrupt
and permanently discontinue Erbitux infusion for serious infusion reactions.
[See WARNINGS AND PRECAUTIONS and DOSAGE
AND ADMINISTRATION.]
Cardiopulmonary Arrest: Cardiopulmonary arrest and/or sudden death occurred
in 2% of 208 patients with squamous cell carcinoma of the head and neck treated
with radiation therapy and Erbitux. Closely monitor serum electrolytes, including
serum magnesium, potassium, and calcium, during and after Erbitux. [See WARNINGS
AND PRECAUTIONS.]

DRUG DESCRIPTION



What are the possible side effects of cetuximab (Erbitux)?

Some people receiving a cetuximab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel short of breath, weak or dizzy, nauseated, itchy, or have wheezing, noisy breathing, or a hoarse voice during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Erbitux »




Erbitux (cetuximab) is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.
Erbitux is a sterile, clear, colorless liquid of pH 7.0 to 7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates. Erbitux is supplied at a concentration of 2 mg/mL in either 100 mg (50 mL) or 200 mg (100 mL), single-use vials. Cetuximab is formulated in a preservative-free solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, 0.41 mg/mL sodium phosphate monobasic monohydrate, and Water for Injection, USP.
Last reviewed on RxList: 8/3/2009




Erbitux Drug Description
ERBITUX®
(cetuximab) Solution for Intravenous Infusion

WARNING: SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST
Infusion Reactions: Serious infusion reactions occurred with the administration
of Erbitux in approximately 3% of patients in clinical trials, with fatal
outcome reported in less than 1 in 1000. [See WARNINGS AND PRECAUTIONS
and ADVERSE REACTIONS.] Immediately interrupt
and permanently discontinue Erbitux infusion for serious infusion reactions.
[See WARNINGS AND PRECAUTIONS and DOSAGE
AND ADMINISTRATION.]
Cardiopulmonary Arrest: Cardiopulmonary arrest and/or sudden death occurred
in 2% of 208 patients with squamous cell carcinoma of the head and neck treated
with radiation therapy and Erbitux. Closely monitor serum electrolytes, including
serum magnesium, potassium, and calcium, during and after Erbitux. [See WARNINGS
AND PRECAUTIONS.]

DRUG DESCRIPTION



What are the possible side effects of cetuximab (Erbitux)?

Some people receiving a cetuximab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel short of breath, weak or dizzy, nauseated, itchy, or have wheezing, noisy breathing, or a hoarse voice during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these...
Read All Potential Side Effects for Erbitux »




Erbitux (cetuximab) is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab is composed of the Fv regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions and has an approximate molecular weight of 152 kDa. Cetuximab is produced in mammalian (murine myeloma) cell culture.
Erbitux is a sterile, clear, colorless liquid of pH 7.0 to 7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates. Erbitux is supplied at a concentration of 2 mg/mL in either 100 mg (50 mL) or 200 mg (100 mL), single-use vials. Cetuximab is formulated in a preservative-free solution containing 8.48 mg/mL sodium chloride, 1.88 mg/mL sodium phosphate dibasic heptahydrate, 0.41 mg/mL sodium phosphate monobasic monohydrate, and Water for Injection, USP.
Last reviewed on RxList: 8/3/2009





Other reviews about Cetuximab on wordpress

Novel EGFR antibody outperforms cetuximab in mouse model of lung cancer
  by Snowcrash
Antibodies that selectively bind and destroy cancer cells represent some of the most promising cancer therapy approaches being developed today. Several of these antibodies have reached the market, […]


Novel EGFR Antibody Outperforms Cetuximab In Mouse Model Of Lung Cancer
  by rognar
Antibodies that selectively bind and destroy cancer cells represent some of the most promising cancer therapy approaches being developed today. Several of these antibodies have reached the market, […]


Lung Cancer Survival Improved by Cetuximab (Erbitux)
  by bmirtsching
ImClone and Bristol Myers Squibb (BMS) released a press announcement on 9/12/07 that cetuximab (Erbitux), a monoclonal anti-epidermal growth factor receptor (EGFR) antibody, improved survival of advanced non-small […]


Cetuximab en el tratamiento de cancer colo-rectal
  by Ruben Roa
Background Cetuximab, an IgG1 chimeric monoclonal antibody against epidermal growth factor receptor (EGFR), has activity against colorectal cancers that express EGFR. Methods From December 2003 […]


Erbitux (Cetuximab) in First-Line Treatment Colorectal Cancer Mangement
  by bmirtsching
CORT has conducted research and treatment studies with the monoclonal anti-EGFR (anti-epidermal growth factor) antibody cetuximab (Erbitux) since 2002.  Early cetuximab studies focused on treatment of disease that was […]


Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
  by journaldokter
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer Jan B. Vermorken, M.D., Ph.D., Ricard Mesia, M.D., Fernando Rivera, M.D., Ph.D., Eva Remenar, M.D., Andrzej Kawecki, M.D., Ph.D., Sylvie […]


NICE issues final guidance on the use of cetuximab for the treatment of head and neck cancer - 24 June 2009
  by kinwahlin
2009/040 NICE issues final guidance on the use of cetuximab for the treatment of head and neck cancer Press release Guidance "The National Institute for Health and Clinical Excellence (NICE) has […]


Head and neck cancer (squamous cell carcinoma) - cetuximab
  by Callier Library
Cetuximab in combination with platinum-based chemotherapy is not recommended for people with recurrent and/or metastatic squamous cell cancer of the head and neck. Healthcare professionals should not stop […]


Drug That Helps Metastatic Colon Cancer of No Benefit in Less Advanced Tumors
  by Karl Oestreich
Journalists:  For links to web-video and audio files, see the bottom of this post.   ASCO Abstract Number: CRA3507 To the surprise of researchers at Mayo Clinic who led a […]


Cetuximab
  by zedie
Cetuximab is an anti-epidermal growth factor receptor (EGFR) monoclonal antibody approved by the US Food and Drug Administration for the treatment of colorectal (CRC) and […]



Other reviews about Cetuximab on web:

Cetuximab (IMC-C225—marketed under the name Erbitux) is a chimeric (mouse/human) monoclonal antibody, an epidermal growth factor receptor (EGFR) inhibitor, given by intravenous ... Cetuximab - Wikipedia, the free encyclopedia


Cetuximab Brand names: Erbitux™Erbitux® Drug Forms: Cetuximab injection (below) Cetuximab Solution for injection Español: Inyección de Cetuximab: Information from Answers.com


This page contains brief information about cetuximab and a collection of links to more information about the use of this drug, related news and research results, and ongoing ... Cetuximab - National Cancer Institute


Cetuximab may cause severe or life-threatening reactions while you receive the medication. These reactions are more common with the first dose of cetuximab, but may occur at any ... Cetuximab Injection: MedlinePlus Drug Information


All about Cetuximab. View complete and up to date Cetuximab information - part of the Drugs.com trusted medication database. Cetuximab Facts and Comparisons at Drugs.com


Physician reviewed cetuximab patient information - includes cetuximab description, dosage and directions. cetuximab medical facts from Drugs.com


Welcome Investigators To access information about cetuximab, an investigational drug, and EGFR, enter your user name and password below. Cetuximab.com: Investigators


Cetuximab is the generic name for Erbitux. C225 is another name for Cetuximab. Cetuximab is a targeted therapy classified as a monoclonal antibody and signal transduction inhibitor ... Cetuximab, Erbitux, C225 - Chemotherapy Drugs, Chemo Drug Side Effects


Learn more about Cetuximab. Find the Web's best health guides, medical reports, news, videos and tools for Cetuximab. Share Cetuximab experiences and get advice from experts. Cetuximab Overview - References, Advice, News, Videos, Coping ...


Learn about the prescription medication Erbitux (Cetuximab), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Erbitux (Cetuximab) Drug Information: Uses, Side Effects, Drug ...





Featured Reviews

Reviews Ciprofloxacin and Dexamethasone

Ciprodex Drug Description CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension DRUG DESCRIPTION What are the possible side effects of ciprofloxacin and dexamethasone otic (Ciprodex)? Stop using...
Read More  |  Review This
Reviews Proglycem

Proglycem Drug Description PROGLYCEM® (diazoxide) Capsules Suspension, USP FOR ORAL ADMINISTRATION DRUG DESCRIPTION What are the possible side effects of diazoxide (Proglycem)? Get emergency medical help if you have any of...
Read More  |  Review This
Reviews Synthroid

Synthroid Drug Description Synthroid® (levothyroxine sodium) Tablets, USP DRUG DESCRIPTION What are the possible side effects of levothyroxine (Levothroid, Levoxyl, Synthroid, Unithroid)? Stop using levothyroxine and get emergency...
Read More  |  Review This
Reviews Vinblastine Sulfate Injection

Vinblastine Sulfate Drug Description VinBLAStine Sulfate for Injection USP WARNING Caution This preparation should be administered by individuals experienced in the administration of vinblastine sulfate. It is extremely important that...
Read More  |  Review This
Reviews Zyprexa

Zyprexa Drug Description ZYPREXA (olanzapine) Tablet for Oral use ZYPREXA ZYDIS (olanzapine) Tablet, Orally Disintegrating for Oral use ZYPREXA IntraMuscular (olanzapine) Injection, Powder, For Solution for Intramuscular use INCREASED...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....